TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Launch One Acquisition Corp. Class A ( (LPAA) ) has shared an update.
On June 25, 2025, Launch One Acquisition Corp. and Minovia Therapeutics Ltd. announced a Business Combination Agreement to create a publicly traded company focused on mitochondrial therapies. The transaction, expected to close in the fourth quarter of 2025, will provide Minovia with capital to accelerate its growth and development pipeline, including clinical and regulatory milestones. The combined entity, Mito US One Ltd., will be listed on Nasdaq, positioning Minovia as a leader in the mitochondrial and longevity markets. The transaction highlights Minovia’s pioneering work in mitochondrial augmentation technology, which has shown promising clinical results and regulatory support, potentially benefiting stakeholders through enhanced market presence and growth opportunities.
More about Launch One Acquisition Corp. Class A
Minovia Therapeutics Ltd. is a clinical-stage biotechnology company based in Haifa, Israel, focused on developing therapies to treat mitochondrial diseases and combat age-related decline. Their lead product, MNV-201, targets mitochondrial dysfunction and is in clinical trials for Pearson Syndrome and Myelodysplastic Syndrome. Minovia aims to expand its offerings in the longevity market and has a U.S. presence.
Average Trading Volume: 40,868
Technical Sentiment Signal: Strong Buy
Current Market Cap: $60.15M
For detailed information about LPAA stock, go to TipRanks’ Stock Analysis page.